As of Nov 19, 2026, 0 of 1 active firms rate ICL a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
ICL EPS & revenue forecast
EPS · NEXT QUARTER
$0.11
Range $0.10 – $0.12 · 2 analysts
Next period, 2 analysts expect ICL Israel Chemicals Ltd to earn $0.11 a share (range $0.10 – $0.12), versus — a year earlier. Full-year consensus is $0.40, growing to $0.45 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 2 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $7.9B, rising to $8.2B next year.
Top analysts covering ICL Israel Chemicals Ltd
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ICL.
#1
Benjamin Theurer
Barclays · Rank #209
Neutral
$6.00+43.2% to target
Overall win rate
45%
+ Follow
#2
Joel Jackson
BMO Capital
Neutral
$6.00+43.2% to target
Coverage
—
+ Follow
#3
ND
Nigel Dally
Morgan Stanley
Neutral
$6.20+48.0% to target
Coverage
—
+ Follow
ICL stock forecast FAQ
What is ICL's average 12-month price target?+
The 1 active firms with a live target average $6.00 for ICL Israel Chemicals Ltd over the next 12 months, ranging from a $6.00 high to a $6.00 low, as of Nov 19, 2026.
Is ICL stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 1 active firms as of Nov 19, 2026, 0 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
How many active Wall Street firms cover ICL?+
1 active firms have a recognized rating on ICL Israel Chemicals Ltd as of Nov 19, 2026, and 1 active firms carry a live 12-month price target.
Who is the most accurate analyst covering ICL?+
Among analysts who currently cover ICL, Benjamin Theurer of Barclays has the strongest overall Quantellect track record (Rank #209). Their current call is Neutral with a $6.00 target.
What is ICL Israel Chemicals Ltd's projected EPS for next quarter?+
The consensus estimate is $0.11 per share (range $0.10 – $0.12) across 2 analysts. Full-year EPS is projected at $0.40, rising to $0.45 the following year.
How much revenue is ICL Israel Chemicals Ltd expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $7.9B, growing to $8.2B next year.
Have analysts been upgrading or downgrading ICL lately?+
As of Nov 19, 2026, 0 of 1 active firms rate ICL a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ICL calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.